Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lucy R. Wall"'
Autor:
Mairéad G. McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sharmila Sothi, Alan Anthoney, Christopher Bell, Alkesh Patel, Jamie B. Oughton, David A. Cairns, Wasat Mansoor, Angela Lamarca, Richard A. Hubner, Juan W. Valle
Publikováno v:
EClinicalMedicine, Vol 60, Iss , Pp 102015- (2023)
Summary: Background: The prognosis for patients with poorly-differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy with no stan
Externí odkaz:
https://doaj.org/article/17e61c62deeb4eef9d3d7c4b9df3c376
Autor:
Zoe Craig, Jayne Swain, Rohini Sharma, Olusola Olusesan Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nicholas Simon Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sothi Sharmila, Alan Anthoney, Alkesh Patel, Angela Lamarca, Richard A Hubner, Juan W. Valle, Mairead Geraldine McNamara
Publikováno v:
Journal of Clinical Oncology. 40:293-293
293 Background: NET-02 was a multi-centre, randomised (1:1), non-comparative phase II trial of nal-IRI/5-FU/folinic acid (ARM A) or docetaxel (ARM B) in pts with progressive PD-EP-NEC, aimed at selecting a treatment for evaluation in a phase III tria
Autor:
Mairead Geraldine McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Olusesan Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sothi Sharmila, Alan Anthoney, Alkesh Patel, Angela Lamarca, Richard Hubner, Juan W. Valle
Publikováno v:
University of Manchester-PURE
646 Background: As demonstrated in the primary analysis of NET-02, nal-IRI/5-FU/folinic acid, but not docetaxel, met the primary endpoint of 6 month (mo) progression-free survival (PFS) rate in pts with progressive PD-EP-NEC. Here, the final results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5245d5cddef5027954fddf62007ec6b
https://research.manchester.ac.uk/en/publications/d7342df9-5ba1-4c38-903d-28b13872121e
https://research.manchester.ac.uk/en/publications/d7342df9-5ba1-4c38-903d-28b13872121e
Autor:
Mairead Geraldine McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Olusesan Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sothi Sharmila, Alan Anthoney, Alkesh Patel, Angela Lamarca, Richard A Hubner, Juan W. Valle
Publikováno v:
University of Manchester-PURE
4005 Background: The prognosis for pts with PD-EP-NEC is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy; there is no standard second-line (2L) treatment (area of unmet need). Methods: This w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02e2ce94e013c2fa2e741c2f3eae181b
https://research.manchester.ac.uk/en/publications/0b8b3098-ca49-4717-b8b4-96b3f9e3d3ef
https://research.manchester.ac.uk/en/publications/0b8b3098-ca49-4717-b8b4-96b3f9e3d3ef